Published in Am Heart J on July 13, 2011
Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ (2012) 1.19
Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. Hypertension (2013) 0.88
Notch signaling change in pulmonary vascular remodeling in rats with pulmonary hypertension and its implication for therapeutic intervention. PLoS One (2012) 0.88
Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy. Curr Vasc Pharmacol (2015) 0.87
Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension. Cell Biochem Biophys (2013) 0.85
Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int (2013) 0.85
Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension. J Biomech Eng (2013) 0.82
C-terminus of ETA/ETB receptors regulate endothelin-1 signal transmission. J Pept Sci (2013) 0.79
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
An evaluation of vardenafil as a calcium channel blocker in pulmonary artery in rats. Indian J Pharmacol (2014) 0.78
Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice. Pulm Circ (2013) 0.77
Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension. Biomark Insights (2016) 0.77
Riociguat: Something new in pulmonary hypertension therapeutics? J Pharmacol Pharmacother (2015) 0.75
Role of endothelin in uteroplacental circulation and fetal vascular function. Curr Vasc Pharmacol (2013) 0.75
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation (2010) 4.66
Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail (2011) 2.92
Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med (2013) 2.36
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol (2007) 2.26
Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation (2010) 2.06
Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol (2008) 2.03
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc (2015) 2.02
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol (2009) 1.80
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest (2006) 1.64
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest (2011) 1.58
World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2012) 1.42
Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest (2010) 1.22
Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant (2011) 1.16
Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson (2012) 1.14
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics (2008) 1.14
Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation (2008) 1.04
Takotsubo cardiomyopathy after treatment of pulmonary arterial hypertension. Pulm Circ (2012) 1.04
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) (2014) 1.03
Three-dimensional transthoracic echocardiography to evaluate cor triatriatum in the adult. J Am Soc Echocardiogr (2006) 1.01
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J (2012) 0.96
Survivor bias and risk assessment. Eur Respir J (2012) 0.96
Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest (2011) 0.93
Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail (2009) 0.91
Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart (2011) 0.89
Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep (2010) 0.89
Right ventricular strain in pulmonary arterial hypertension: a 2D echocardiography and cardiac magnetic resonance study. Echocardiography (2014) 0.89
Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. J Heart Lung Transplant (2012) 0.85
Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest (2009) 0.84
Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant (2009) 0.83
Prostacyclin and Oral Vasodilator Therapy in Sarcoidosis-Associated Pulmonary Hypertension: A Retrospective Case Series. Chest (2015) 0.83
One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant (2013) 0.83
Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest (2011) 0.81
Prognostication in pulmonary arterial hypertension. Heart Fail Clin (2012) 0.81
Three-dimensional modeling of the right ventricle from two-dimensional transthoracic echocardiographic images: utility of knowledge-based reconstruction in pulmonary arterial hypertension. J Am Soc Echocardiogr (2013) 0.81
Three-dimensional analysis of interventricular septal curvature from cardiac magnetic resonance images for the evaluation of patients with pulmonary hypertension. Int J Cardiovasc Imaging (2011) 0.80
Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points. Circ Cardiovasc Imaging (2013) 0.80
Relative adrenal insufficiency in severe congestive heart failure with preserved systolic function: a case report. J Cardiovasc Med (Hagerstown) (2007) 0.79
Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition? Curr Med Res Opin (2006) 0.79
Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol (2013) 0.77
Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. Thromb Haemost (2012) 0.77
Something subtle about death: isolated systolic pulmonary pressure. Circulation (2009) 0.77
Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure. Curr Heart Fail Rep (2014) 0.77
Obliteration of the left atrial appendage for prevention of thromboembolism. J Am Coll Cardiol (2003) 0.76
New pharmacotherapies for pulmonary hypertension: where do they fit in? Curr Hypertens Rep (2014) 0.75
Author's reply. Pulm Circ (2013) 0.75
Polymorphisms of adrenergic receptors and the risk of heart failure. N Engl J Med (2003) 0.75
Off-pump coronary bypass surgery. N Engl J Med (2003) 0.75
Pulmonary arterial hypertension with right ventricular failure: the left forgotten ventricle. Chest (2013) 0.75
[New trial designs and potential therapies for pulmonary artery hypertension]. Turk Kardiyol Dern Ars (2014) 0.75
Out with the old, in with the new: an updated risk stratification equation for pulmonary arterial hypertension. Expert Rev Cardiovasc Ther (2010) 0.75
Management of pulmonary hypertension and right heart failure in the intensive care unit. Curr Hypertens Rep (2015) 0.75
Treadmill testing improves survival prediction models in pulmonary arterial hypertension. Am Heart J (2011) 0.75